S100: Risk of Neutropenia with the Use of Ceftaroline: A Review
Poster Presenter
Tuiana Brown
PharmD Candidate 2025
Chicago State University United States
Objectives
The objective of the study was to determine the risk of ceftaroline use with neutropenia.
Method
A literature search was conducted on PubMed, Embase, and Web of Science to identify all studies examining the association between ceftaroline use and neutropenia. We included studies from 2010 to 2023 as ceftaroline was approved by the FDA in 2010.
Results
Search results produced eight published articles that underwent review by the authors. Two case studies and six observational studies highlighted a common theme and outcome: extended use of ceftaroline with exposure greater than two consecutive weeks is associated with an increased risk of neutropenia. After controlling for other covariates, ceftaroline therapy continued to remain a risk factor for developing neutropenia (adjusted OR: 3.97, 95% CI: 1.61-9.78) compared to therapy with other antibiotics. Of note, patients who received ceftaroline were treated for more consecutive days compared to the patients on comparable antibiotics (median: 27 days, IQR: 18-39 vs. median: 18 days, IQR: 15-26).
Conclusion
After consideration of the reviewed literature, it is clear that the association between ceftaroline and neutropenia warrants additional research to fully elucidate the risk of ceftaroline and the development of neutropenia. Our research indicates that across the United States and in varying patient populations the use of ceftaroline is positively associated with the development of neutropenia after prolonged use both on and off label. Since the first case report of neutropenia associated with ceftaroline use was published in 2013, three years after FDA approval, these chart reviews have continued to demonstrate this association with the culmination of a large multi-center retrospective cohort study in 2017. Despite the limitations of this literature, the cross-study agreement regarding prolonged therapy and the recovery of ANC within one month of therapy discontinuation suggests that this is not a spurious association and deserves more rigorous research.
